This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Murphey, L. J. Articles by Brown, N. J. Search for Related Content PubMed PubMed Citation Articles by Murphey, L. J. Articles by Brown, N. J. Related Collections Cardiovascular Pharmacology ACE/Angiotension receptors Fibrinolysis Endothelium/vascular type/nitric oxide

(Circulation. 2000;102:829.)
© 2000 American Heart Association, Inc.

Brief Rapid Communications

Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism Modulates the Human In Vivo Metabolism of Bradykinin

Laine J. Murphey, MD, PhD; James V. Gainer, MD; Douglas E. Vaughan, MD; Nancy J. Brown, MD

From the Divisions of Clinical Pharmacology (L.J.M., J.V.G., N.J.B.) and Cardiovascular Medicine (D.E.V.), Departments of Medicine and Pharmacology, Vanderbilt University Medical Center and Veterans Affairs Medical Center (D.E.V.), Nashville, Tenn.

Correspondence to Nancy J. Brown, MD, 560-MRB1, Nashville, TN 37232-6602. E-mail Nancy.Brown{at}mcmail.vanderbilt.edu

Background—Bradykinin is a cardioprotective peptide metabolized by the angiotensin-converting enzyme (ACE). An insertion/deletion (I/D) polymorphism in the ACE gene determines plasma ACE levels. The D allele is associated with cardiovascular disease, which may relate to enhanced angiotensin II production or to increased bradykinin degradation to the inactive metabolite bradykinin 1–5 (BK1–5). Therefore, we determined the effect of the ACE I/D polymorphism on human bradykinin metabolism in vivo.

Methods and Results—Bradykinin (400 ng/min) was infused into the brachial artery of volunteers with ACE I/I, I/D, or D/D genotypes (n=9 each). The bradykinin and BK1–5 levels in forearm venous return were quantified by liquid chromatography–mass spectroscopy. Plasma ACE activity was highest in those with the D/D genotype (36.8±6.2 U/mL), intermediate in those with the I/D genotype (25.3±3.3 U/mL), and lowest in those with the I/I genotype (20.3±2.3 U/mL; P=0.017 for effect of number of D alleles). Bradykinin concentrations were 726±242, 469±50, and 545±104 fmol/mL in I/I, I/D, and D/D subjects, respectively (P>0.10). Significant correlations existed between the number of D alleles and BK1–5 concentrations (1113±290, 1520±318, and 1887±388 fmol/mL in the I/I, I/D, and D/D groups, respectively; P=0.027) and the ratio of BK1–5 to bradykinin (1.87±0.35, 3.09±0.40, and 4.31±0.97 in the I/I, I/D, and D/D volunteers, respectively; P=0.010). The venous blood BK1–5:bradykinin ratio correlated with plasma ACE activity (r²=0.16, P=0.039), and total kinin concentration correlated with net tissue plasminogen activator release across the forearm (r²=0.20, P=0.027).

Conclusions—The ACE D allele has a significant effect on the in vivo degradation of bradykinin in humans. The ratio of BK1–5:bradykinin may serve as a marker for tissue ACE activity.

Key Words: bradykinin • metalloproteinases • metabolism • endothelium

This article has been cited by other articles:

				Min Pan, M.-H. Jiang, M.-F. Wei, Z.-H. Liu, W.-P. Jiang, H.-H. Geng, Z.-C. Cui, D.-L. Zhang, and J.-H. Zhu Association of Angiotensin-Converting Enzyme Gene 2350G>A Polymorphism With Myocardial Infarction in a Chinese Population Clinical and Applied Thrombosis/Hemostasis, August 1, 2009; 15(4): 435 - 442. [Abstract] [PDF]

				L. J. Murphey, H. A. Malave, J. Petro, I. Biaggioni, D. W. Byrne, D. E. Vaughan, J. M. Luther, M. Pretorius, and N. J. Brown Bradykinin and Its Metabolite Bradykinin 1-5 Inhibit Thrombin-Induced Platelet Aggregation in Humans J. Pharmacol. Exp. Ther., September 1, 2006; 318(3): 1287 - 1292. [Abstract] [Full Text] [PDF]

				F.A. Sayed-Tabatabaei, B.A. Oostra, A. Isaacs, C.M. van Duijn, and J.C.M. Witteman ACE Polymorphisms Circ. Res., May 12, 2006; 98(9): 1123 - 1133. [Abstract] [Full Text] [PDF]

				N. S Hopkinson, K. I Eleftheriou, J. Payne, A. H Nickol, E. Hawe, J. Moxham, H. Montgomery, and M. I Polkey +9/+9 Homozygosity of the bradykinin receptor gene polymorphism is associated with reduced fat-free mass in chronic obstructive pulmonary disease. Am. J. Clinical Nutrition, April 1, 2006; 83(4): 912 - 917. [Abstract] [Full Text] [PDF]

				L. Lin, L. Finn, J. Zhang, T. Young, and E. Mignot Angiotensin-converting Enzyme, Sleep-disordered Breathing, and Hypertension Am. J. Respir. Crit. Care Med., December 15, 2004; 170(12): 1349 - 1353. [Abstract] [Full Text] [PDF]

				A. G. Williams, S. S. Dhamrait, P. T. E. Wootton, S. H. Day, E. Hawe, J. R. Payne, S. G. Myerson, M. World, R. Budgett, S. E. Humphries, et al. Bradykinin receptor gene variant and human physical performance J Appl Physiol, March 1, 2004; 96(3): 938 - 942. [Abstract] [Full Text] [PDF]

				N. Takahashi, J. R. Hagaman, H.-S. Kim, and O. Smithies Minireview: Computer Simulations of Blood Pressure Regulation by the Renin-Angiotensin System Endocrinology, June 1, 2003; 144(6): 2184 - 2190. [Abstract] [Full Text] [PDF]

				C. Adessi, M.-J. Frossard, C. Boissard, S. Fraga, S. Bieler, T. Ruckle, F. Vilbois, S. M. Robinson, M. Mutter, W. A. Banks, et al. Pharmacological Profiles of Peptide Drug Candidates for the Treatment of Alzheimer's Disease J. Biol. Chem., April 11, 2003; 278(16): 13905 - 13911. [Abstract] [Full Text] [PDF]

				D. A. Rosenbaum, M. Pretorius, J. V. Gainer, D. Byrne, L. J. Murphey, C. A. Painter, D. E. Vaughan, and N. J. Brown Ethnicity Affects Vasodilation, but Not Endothelial Tissue Plasminogen Activator Release, in Response to Bradykinin Arterioscler Thromb Vasc Biol, June 1, 2002; 22(6): 1023 - 1028. [Abstract] [Full Text] [PDF]

				P. Porcu, C. Emanueli, M. Kapatsoris, J. Chao, L. Chao, and P. Madeddu Reversal of Angiogenic Growth Factor Upregulation by Revascularization of Lower Limb Ischemia Circulation, January 1, 2002; 105(1): 67 - 72. [Abstract] [Full Text] [PDF]

				C. Oliveri, M. P. Ocaranza, X. Campos, S. Lavandero, and J. E. Jalil Angiotensin I-Converting Enzyme Modulates Neutral Endopeptidase Activity in the Rat Hypertension, September 1, 2001; 38(3): 650 - 654. [Abstract] [Full Text] [PDF]

				G. Arcaro, A. Solini, T. Monauni, A. Cretti, B. Brunato, A. Lechi, R. Fellin, M. Caputo, C. Cocco, E. Bonora, et al. ACE Genotype and Endothelium-Dependent Vasodilation of Conduit Arteries and Forearm Microcirculation in Humans Arterioscler Thromb Vasc Biol, August 1, 2001; 21(8): 1313 - 1319. [Abstract] [Full Text] [PDF]

				S. B. Harrap and S. Petrou Utility of genetic approaches to common cardiovascular diseases Am J Physiol Heart Circ Physiol, July 1, 2001; 281(1): H1 - H6. [Full Text] [PDF]

				D.R. Woods, D. Brull, and H. Montgomery Increased QT dispersion with the D-allele of the ACE polymorphism Eur. Heart J., April 2, 2001; 22(8): 618 - 621. [PDF]